Effectiveness and safety of teclistamab for relapsed or refractory multiple myeloma: a systematic review and meta-analysis
BackgroundMultiple myeloma (MM) is a hematological malignancy with limited treatment options for patients with relapsed/refractory MM (RRMM). Teclistamab, a B-cell maturation antigen (BCMA) × CD3 bispecific antibody, has shown promising results in clin…